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hydroxy-vitamin D deﬁciency, total body irradiation, and
growth hormone deﬁciencies. This report is a single insti-
tutions retrospective analysis of bone density evaluation and
incidence of OP/ON following pediatric SCT.
Method: From 2003 to 2012, 17 patients undergoing allo-
geneic stem cell transplantation (5 AML, 8 ALL, 1 CML, 1 NHL,
2 aplastic anemia) received lipid proﬁle evaluation per-
formed at Loma Linda University Medical Center by a Roche
Modular System Photometric Assay and 25-OH vitamin D
analysis at Mayo Clinic, Rochester Minnesota. 15 of these
patients also had bone density testing by a dual-energy x-ray
absorptiometry (DEXA) scan. With osteoporosis and osteo-
penia deﬁned as Z score <-1 and <-2.5 respectively. 9
patients received stem cells from HLA matched unrelated
donors (MUD) and 8 HLA matched related sibling donors
(MRD). Patients were treated with: (14) 1200 cGy total body
irradiation, 1500mg/m2 etoposide, 120 mg/kg cyclophos-
phamide; (1) busulfan (16 doses), 200 mg/kg cyclophos-
phamide; (2) ATG, 200 mg/kg cyclophosphamide, 200 cGy
total body irradiation. GVHD prophylaxis was cyclosporine
for MRD or tacrolimus for MUD and short course metho-
trexate. Patient's age at testing ranged from 7 to 23 years,
mean 13.5 years.
Result: OP was extremely common after SCT with bone
density Z score of lower then -1 in 13/15 tested. 25-OH Vit D
was low in 15 /17 tested. Elevated cholesterol was present in
8/17 and cholesterol/HDL ratio (>3.5%) in 12/15 tested.
Stratiﬁcation of patients by history of chronic GVHD or
moderate to severe acute GVHD showed that while meta-
bolic abnormality was present in both groups, symptomatic
OP/ON were conﬁned to the chronic GVHD group. Among 4
patients with no history of GVHD, 2/4 had normal bone
density, 2/4 had normal lipids, and none had symptomatic
OP/ON. In contrast, among 13 patients with GVHD all 10/10
tested had diminished bone density, 9/10 tested had elevated
lipid ratios, and 5/13 had symptomatic OP/ON with 4
requiring surgery. Symptomatic OP/ON events resulted in the
need for joint replacement of the knees, hips and shoulders.
In addition, patients had fractures of the long bones needing
internal ﬁxation devices to help with the repair.
Conclusion: These results suggest that lipid metabolism
abnormalities and low Vit D levels are common after SCT and
interventions to normalize these abnormalities may have the
greatest impact on symptomatic ON/OP in patients with
GVHD.210
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Background: Neurocognitive function is vulnerable in the
formative pediatric years to transplant conditioning regimen
especially those using fractionated total body irradiation
(FTBI). However, FTBI improves disease free survival (DFS) in
lymphoid malignancies. Our institution has previously
described a novel conditioning regimen using low dose
single fraction TBI (SDTBI) delivered at a high dose rate. DFS
was comparable to recipients of fractionated TBI, and early
toxicities were minimal (Druley, BMT 2009). Our hypothesisis that SDTBI based myeloablative conditioning is associated
with less neurotoxicity and can preserve neurocognitive
functions in children.
Aim: To review neurocognitive function in children
following SDTBI (550 cGy) and cyclophosphamide- based
myeloablative transplant conditioning for hematologic
malignancies pre and 1 year post transplant.
Methods: A total of 45 consecutive children transplanted for
hematologic malignancies (ALL, AML, NHL) between March
1998 and January 2006 that survived beyond 1 year after
transplant were identiﬁed. The conditioning regimen con-
sisted of cyclophophamide 50 mg/kg on days -3 and -2, and
SDTBI (550 cGy) on day -1. Fifteen had neurocognitive testing
completed before and at least 1 year post transplant. This
testing comprised of a comparative analysis of IQ and neu-
rocognitive function using Wechsler intelligence scales
selected based on the child's age.
Result: Full scale (FSIQ), verbal (VIQ), and performance or
non-verbal (PIQ) IQs were compared. Using a greater than 1
SD loss (or greater than 15 point loss) criterion as a gross
marker for signiﬁcant decline at the individual patient level.
Fifteen patients had an average age was 10.7 years (range 1-
20.5). No patient showed a decline in FSIQwith the exception
of one. This child underwent a second myeloablative trans-
plant one year after the ﬁrst; FSIQ declined by 16 points. One
child's VIQ declined 23 points; two others’ PIQ declined by 16
and 21 points, respectively.
Conclusion: Among a limited cohort of SDTBI BMT, the
majority showed an overall stability or lack of signiﬁcant
decline in neurocognitive function one year post transplant.
In contrast, previous reports show decline one year post
transplant in children receiving FTBI (Phipps S et al, JCO
2008; Shah et al, PBC 2008). These data provide an initial
insight into the effects of SDTBI based conditioning on neu-
rocognition in children. Future studies will expand the
analysis to further analyze exposure to CNS toxic treatments
and to examine more detailed cognitive measures for
domain speciﬁc trends. We will also look at patients that
received FTBI and Bulsulfan/cyclosphosphamide.211
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Introduction: Hematopoietic stem cell transplantation
(HSCT) is an increasingly utilized treatment option for
adolescents with a wide range of life-threatening diagnoses.
Following discharge, adolescents who have undergone HSCT
must manage a complex treatment regimen including
numerous oral and/or intravenous medications. Suboptimal
adherence to this medication regimen may result in sub-
therapeutic medication exposure, potentially compromising
treatment effectiveness and, subsequently, increasing the
risk of adverse medical outcomes. During adolescence,
individuals are increasingly likely to experience stressors
Table 1
M (SD) Range
Percentage of prescribed doses taken 70.39 (21.47) 28.21 e 92.50
Percentage of days with correct
number of doses taken
55.43 (23.11) 20.51 e 88.18
Percentage of days with partial
adherence (1 - 99%)
26.75 (17.18) 8.18 e 56.82
Percentage of days with no prescribed
doses taken
17.81 (22.59) 0 e 64.10
Length of medication interruptions
( 24 hours between doses), days
4.46 (7.45) 0 e 36
Table 1
NIH Consensus Project Ancillary Therapy and Supportive Care Recommen-
dations for Eye GVHD and BFS Survey 1 Results
Therapy Indication/Severity
N with
GVHD
who
tried
Mod
success
Sig
success
Topical Mild
Artiﬁcial Tears 44 45% 7%
Viscous ointment/tears NIS N/A N/A
Topical Moderate/severe
Cyclosporine eye drops 35 8% 0%
Topical steroid drops 28 29% 0%
Lacriserts 10 10% 0%
Oral Moderate/severe
Cevimeline NIS N/A N/A
Pilocarpine NIS N/A N/A
Doxycycline 26 23% 0%
Surgical Moderate/severe
Punctual occlusion:
plugs
36 16% 0%
Punctual occlusion:
cautery
20 20% 5%
Partial tarsorrhaphy 5 40% 0%
Eyewear/
environmental
Moderate/severe
Occlusive eye wear NIS N/A N/A
Lid care/warm
compress
NIS N/A N/A
Bandage contact lens 6 33% 0%
Treatment
not widely
available
Moderate/ severe
Autologous serum eye
drops
8 12.5% 12.5%
Gas-permeable contact
lens (Boston scleral
lens prosthesis,
www.bostonsight.org)*
41 17% 76%
NIS indicates, not in survey; N/A indicates, not applicable
* BostonSight PROSE treatment
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adherence. As such, it is important to understand adherence
in this potentially at-risk group. This study is the ﬁrst to
describe patterns of adherence in adolescents who have
undergone HSCT.
Method: Data for this study are from a larger project
examining adherence in pediatric HSCT recipients. Partici-
pants included eight adolescents (ages 12-18) who had
undergone HSCT and their caregivers. Participants used
Medical EventMonitors (MEMS), electronic pill bottles that
report time-stamped indications of bottle openings to track
adherence for the duration of the study (9 mo.), until all oral
medications were discontinued (n ¼ 2), or until the device
was lost/no longer provided for download (n ¼ 2), resulting
in an average of 195.63 monitored days (SD ¼ 119.87 days).
Daily adherence was calculated by dividing the number of
recorded MEMS openings per day by the number of
prescribed doses for that day. The average length of medi-
cation interruptions ( 24 hours between doses) was
calculated for participants prescribed daily medication (n ¼
7). Caregivers provided demographics. Clinical characteris-
tics were obtained via chart review.
Results: Participants were primarily male (63%), Caucasian
(75%), and non-Hispanic (75%). On average, participants were
14.07 years of age (SD ¼ 1.41 years) and received their
transplant at 14.00 years of age (SD ¼ 1.41 years). Adherence
data are presented in Table 1. Participant level data will also
be presented.
Discussion: Overall, participants struggled to adhere to
medication schedules, taking 70% of prescribed doses and
demonstrating perfect adherence on fewer than four out of
seven days per week. Adherence rates are similar to those
observed in other pediatric populations and demonstrate the
importance of routinely assessing adherence in adolescents
who have undergone HSCT.
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Introduction: Approximately 50% of HSCT recipients
develop chronic GVHD and of these 60% suffer from
moderate to severe ocular GVHD. The symptoms of ocular
GVHD (OCGVHD), blurry vision, burning, foreign body
sensation, pain, excessive tearing, and photophobia, have
negative effects on quality of life (QOL). We attempt to
identify opportunities to increase awareness, acceptance,
access to treatment, and care coordination that can improve
QOL in OCGVHD.
Methods: Retrospective review of 2 online surveys con-
ducted by Boston Foundation for Sight (BFS) and keyword
searches of BBMT and PubMed. Survey 1 in 2009 included1127 self-selected respondents from emails sent to 700 BFS
patients and posts on 3 patient websites: Dry Eye Zone, NKCF
and SJS Foundation. 51 reported OCGVHD (BFS patients
N¼41) and 476 dry eye without COGVHD (BFS patients
N¼147). Survey 2 in 2011 included 149 self-selected
respondents from emails to 900 PROSE treatment patients
seen in previous 5 years. 19 reported OCGVHD and 94 dry eye
(also OCGVHD N¼17).
Results: Survey 1 revealed 26% of COGVHD BFS patients ﬁrst
heard about PROSE treatment from an eye doctor, 26% BMT
transplant team, 28% other medical doctors and 20% other
sources; versus 46%, 0%, 1.5%, and 52.5% respectively for dry
eye patients without COGVHD. Table 1 presents respondent
reported experience and success with ancillary and
supportive care recommendations for Eye GVHD from 2006
NIH consensus project. Survey 2 revealed 84% of OCGVHD
reported PROSE devices daily wear. 79% would have pursued
the treatment months or years earlier if possible, and 31% of
these cited lack of awareness of PROSE treatment as
a delaying factor. 11% consulted 6 or more ophthalmologists
before ﬁnding PROSE; 11% 4 or more; and 28% 3 or more.
Search of BBMT database on 6 combinations of the terms
“ocular”, “chronic”, “graft versus host disease” and/or
“GVHD” anywhere in title or body yields 12 citations
including meeting abstracts. Search of PubMed using same
keyword criteria for title only yields 22 citations.
Conclusions: Despite 2006 consensus workshop recom-
mendations, including multi-disciplinary coordinated care
by an ophthalmologist knowledgeable about HCT and GVHD,
we have found that with OCGVHD receive higher level
